Montelukast (MLK) is a cysteinyl leukotriene receptor 1 (CysLT1R) and G protein-coupled receptor 17 (GPR17) antagonist, approved as adjuvant therapy for asthma in both children and adults [12–14]. The gene discussed is CYSLTR1; the disease is asthma.